Floatz logo

ETOPOSIDE

Primary Central Nervous System Lymphoma

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Primary Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB
Cyclophosphamide
Juan P. Alderuccio, MD
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Ono Pharmaceutical Co., Ltd.
Phase 4BB
DEXAMETHASONE
Allison Winter
Phase 4BB

View all 36 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →